Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com
PAK1 Emerges as a Potential Target in Ibrutinib-Resistant CLL
September 20th 2021A genome-wide look into changes in three-dimensional chromatin organization between ibrutinib-resistant and parental chronic lymphocytic leukemia cells illustrated the involvement of PAK1 as an oncogenic driver in CLL.
Read More
Goy Taps Into the True Potential of Precision Medicine in Oncology
September 18th 2021Current approaches to precision medicine in oncology have been fruitful, but require better integration and utilization of available resources to inform sustainable and effective drug development and clinical care, according to Andre Goy, MD.
Read More
Global Maximum-Tolerated Dose of Mobocertinib Found Tolerable in Japanese Patients With NSCLC
September 16th 2021Mobocertinib displayed a manageable safety profile across 40-mg, 120-mg, and 160-mg dose cohorts in Japanese patients with non–small cell lung cancer, which, when coupled with pharmacokinetic analysis, led to the determination of 160 mg as the maximum tolerated dose and recommended phase 2 dose for further study in this population.
Read More
COVID-19 Leads to High Hospitalization and Mortality in Malignant Pleural Mesothelioma
September 8th 2021Approximately 20% of patients with malignant pleural mesothelioma were diagnosed with COVID-19 during the first year of the pandemic at the Vall d’Hebron University Hospital, leading to a high hospitalization and mortality rate.
Read More
ESMO Publishes Guidelines for the Management of Solid Tumor Brain Metastases
September 7th 2021The European Association of Neuro-Oncology and ESMO have released clinical practice guidelines, which provide management recommendations for the diagnosis, treatment, and follow-up of patients with solid tumor brain metastases.
Read More
Pembrolizumab Plus Lenvatinib Improves Survival in dMMR Endometrial Cancer
September 7th 2021The combination of pembrolizumab and lenvatinib led to a statistically significant improvement in progression-free survival and overall survival in patients with mismatch repair deficient advanced endometrial cancer following platinum-based chemotherapy.
Read More
Biomarkers of response to immunotherapy, characterized by high interferon signaling and expression of MHC-II related genes, predicted for improved survival in patients with advanced hepatocellular carcinoma following immediate treatment with a PD-1 inhibitor but not in those who had first received treatment with a TKI.
Read More
Genomic-Adjusted Radiation Dose Is Associated With First Recurrence and Survival in Solid Tumors
September 3rd 2021Genomic-adjusted radiation dose demonstrated a significant association with time to first recurrence and overall survival in patients with certain solid tumors who had been treated with radiation therapy, indicating that genomics should be used to guide radiation dosing decisions.
Read More
The addition of venetoclax to daratumumab, bortezomib, and dexamethasone or daratumumab and dexamethasone alone led to a response rate of more than 90% in patients with relapsed/refractory multiple myeloma, which proved durable in the majority of patients, particularly those with t(11;14) translocation.
Read More
Co-occurring 22q11.22 Deletions and IKZF1 Alterations Linked With Poor Outcomes in Pediatric B-ALL
August 30th 2021Co-occurring focal 22q11.22 deletions and IKZF1 alterations were associated with inferior outcomes vs IKZF1 alterations alone in pediatric patients with B-cell acute lymphoblastic leukemia.
Read More
Nivolumab and Tumor-Infiltrating Lymphocyte Regimen Elicits Activity in Metastatic NSCLC
August 27th 2021Nivolumab followed by tumor-infiltrating lymphocyte therapy and maintenance nivolumab demonstrated a suitable safety profile and antitumor activity in patients with metastatic non–small cell lung cancer.
Read More
Six-months of adjuvant androgen suppression plus 74 Gy or 78 Gy of concurrent external-beam radiation led to a statistically significant improvement in event-free survival and disease-free survival but failed to improve distant metastasis-free survival and overall survival vs external-beam radiation alone in patients with intermediate-risk prostate cancer.
Read More
Palbociclib/Ruxolitinib Combo Shows Preclinical Promise in Myelofibrosis
August 19th 2021Palbociclib plus ruxolitinib led to normalized blood leukocyte counts, reduced splenomegaly, and significantly improved bone marrow fibrosis in JAK2 V617F and MPLW515L mouse models of myelofibrosis, suggesting that the combination could provide therapeutic benefit to patients with the malignancy.
Read More
Zandelisib Plus Rituximab Under Study in Indolent Non-Hodgkin Lymphoma
August 13th 2021Zandelisib plus rituximab is being evaluated as a potentially chemotherapy-free treatment strategy vs standard chemoimmunotherapy in patients with indolent non-Hodgkin lymphoma in first relapse in the ongoing, phase 3 COASTAL trial.
Read More
Topical BRAF Inhibitor, LUT014, Dosed in First US Patients With mCRC for Acneiform Lesions
August 10th 2021The first participants from the United States have been dosed with LUT014, a novel, topical BRAF inhibitor in a phase 2 trial that is evaluating the agent in patients with metastatic colorectal cancer who have developed dose-limiting acneiform lesions following treatment with an EGFR inhibitor.
Read More
ASCO 2021 Delivers Personalized Treatment Approaches Across Breast Cancer
August 6th 2021Refining treatment is not only a key aim of research in breast cancer but a greater possibility in the clinic with neoadjuvant and adjuvant PARP inhibitors, HER2 monoclonal antibodies, and greater stratification of genomic risk.
Read More